Now Playing
Commentary|Videos|April 29, 2024
Prevalence of NRG1 Fusions in Lung Cancer
Author(s)Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses the prevalence of NRG1 fusions in lung cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.
Longer DeLLphi-304 follow-up showed sustained OS, PFS, and response durability with tarlatamab in second-line small cell lung cancer.
Izalontamab brengitecan improved progression-free survival vs chemotherapy in EGFR-mutated lung cancer after a third-generation EGFR inhibitor.
Frontline savolitinib plus osimertinib improved progression-free survival vs osimertinib alone in EGFR-mutated, MET-overexpressing lung cancer.
The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.
In SAFFRON, the oral EGFR/MET inhibitor pairing extended survival over platinum/pemetrexed in MET-driven lung cancer that progressed on osimertinib.
Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
2
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
3
T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer
4
Basser Center for BRCA Awards 2026 Global Prize to Judy Garber
5